Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

Denmark open to ‘Golden Dome’ talks after Trump touts framework Greenland deal

January 22, 2026

Prime Minister Mette Frederiksen holds a press conference in the Mirror Hall at the Prime Minister’s Office, at Christiansborg in Copenhagen, Denmark, on January 13, 2026. Nurphoto | Nurphoto | Getty Images Danish Prime Minister Mette Frederiksen on Thursday welcomed U.S. President Donald Trump’s Greenland pivot, saying the country is prepared to hold talks with […]

World

European markets set to rocket on Trump’s Greenland ‘deal,’ tariffs retreat

January 22, 2026

US President Donald Trump delivers a special address during the World Economic Forum (WEF) annual meeting in Davos on January 21, 2026. The World Economic Forum takes place in Davos from January 19 to January 23, 2026. Fabrice Coffrini | Afp | Getty Images LONDON — European stocks are expected to open higher Thursday after […]

World

Fossil fuels are a ‘crutch’: How AI’s unlikely winner could be renewable energy

January 22, 2026

Stalled demand for energy in Europe pushed investors away from renewables, but artificial intelligence could see cash flow back into the sector, while also uplifting fossil fuels. Global electricity generation from renewables is expected to jump by 60% in 2030, accounting for 45% of total electricity output, per the International Energy Agency. Almost 50% of […]